Organogenesis (ORGO) to Release Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Organogenesis to post earnings of $0.21 per share and revenue of $172.6750 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Organogenesis Price Performance

Organogenesis stock opened at $3.84 on Thursday. The stock has a market capitalization of $487.33 million, a P/E ratio of -32.00 and a beta of 1.46. Organogenesis has a 12-month low of $2.61 and a 12-month high of $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The firm’s 50-day moving average is $4.41 and its two-hundred day moving average is $4.62.

Insider Activity

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director owned 2,565,591 shares of the company’s stock, valued at approximately $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 500,000 shares of company stock worth $2,620,120. 33.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Organogenesis

Several hedge funds and other institutional investors have recently modified their holdings of ORGO. Quarry LP acquired a new stake in Organogenesis during the 3rd quarter worth approximately $25,000. Federated Hermes Inc. lifted its position in Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after buying an additional 2,953 shares in the last quarter. Walleye Capital LLC purchased a new stake in Organogenesis during the second quarter worth approximately $45,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Organogenesis in the fourth quarter worth $57,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Organogenesis by 57.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock valued at $61,000 after acquiring an additional 5,273 shares during the period. 49.57% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on ORGO. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Organogenesis in a research note on Friday, December 26th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Organogenesis has a consensus rating of “Hold” and an average target price of $8.00.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.